Pluronic F-127 gel preparation as an artificial skin in the treatment of third-degree burns in pigs

• Published in: Journal of biomedical materials research Vol. 21; no. 9; p. 1135
• Main Authors: Nalbandian, R M, Henry, R L, Balko, K W, Adams, D V, Neuman, N R
• Format: Journal Article
• Language: English
• Published: United States 01-09-1987
• Subjects: Animals; Artificial Organs; Burns - therapy; Evaluation Studies as Topic; Gels; Poloxalene - therapeutic use; Polyethylene Glycols - therapeutic use; Skin; Swine; Wound Healing
• ISSN: 0021-9304
• DOI: 10.1002/jbm.820210907

A blinded study was designed to provide qualitative and quantitative evaluation on the possible therapeutic benefits of the use of Pluronic Polyol F-127 as a substitute skin in standardized third-degree thermal burns. Three separate burns, approximately 1600 mm2, were induced on the shaved backs of young, anesthetized pigs. Each animal served as its own control. One burn site was left untreated while the other two sites were covered with coded preparations of the Pluronic F-127 gel with additives. Polaroid photographs with a fixed focal-length camera were taken of all burn sites for planimetry analysis. Biopsies taken confirmed that third-degree burns were achieved. The pigs were followed for 30 days. The rate of healing of third-degree thermal burns was significantly accelerated over control sites when treated with Pluronic Polyol F-127 plus propylene glycol. When the bacteriostatic agent Garamycin was also added, the rate of healing remained significantly better than untreated controls. With the addition of Piracetam, burn wound healing was actually retarded within 30 days, when applied topically. Thus, wound healing was both accelerated and retarded as a function of the particular Pluronic preparation used to treat specific burn sites. This experimental modulation of wound healing suggests that the non-ionic poloxamer, Pluronic F-127, can significantly enhance the rate of wound healing by some unknown mechanism, possibly by stimulation of epithelial growth factor (EGF).